3 citations
,
November 2022 in “Frontiers in oncology”
This study found that while serum zinc concentrations were not associated with developing gynecologic cancers, zinc deficiency was linked to a higher recurrence rate.
4 citations
,
February 2024 in “The Journal of Urology”
This study reports that adding androgen deprivation therapy to salvage radiation therapy for patients with non-metastatic biochemical recurrence of prostate cancer after radical prostatectomy improves progression-free survival, particularly in those with higher post-prostatectomy PSA levels.
This study reported that high cholesterol levels were linked to increased prostate cancer risk, while selenium supplementation affected gene expression, suggesting nutritional and clinical factors might influence prostate cancer risk and biology.
10 citations
,
May 2020 in “Journal of The American Academy of Dermatology”
This study found that spironolactone was not independently associated with increased breast cancerrecurrence and may be considered for treating alopecia in survivors.
The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.
Hair transplants are not permanent and require medication like finasteride or dutasteride to maintain results, as transplanted hair can still thin over time. Individuals with a history of prostate cancer may need to avoid these medications due to potential health risks.
Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.
The post discusses a user's experience with hair loss treatments, specifically topical finasteride, minoxidil, and micro-needling, and their plan to switch to oral versions and add Dutasteride. The conversation includes various responses, with some users sharing their own experiences and side effects, and others expressing desire for a more permanent hair loss solution.
The conversation humorously discusses the prioritization of curing cancer over solving baldness, with mentions of treatments like finasteride and dutasteride. Participants express frustration over the lack of focus on hair loss solutions compared to cancer research.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.